Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?

Medical Hypotheses

Volumn 75, Issue 6, 2010, Pages 605-609

  Wegrzyn, Grzegorz ^a   Jakóbkiewicz Banecka, Joanna ^a   Narajczyk, Magdalena ^a   Wiśniewski, Andrzej ^a   Piotrowska, Ewa ^a   Gabig Cimińska, Magdalena ^a   Kloska, Anna ^a   Słomińska Wojewódzka, Monika ^a   Korzon Burakowska, Anna ^b   Wegrzyn, Alicja ^a  

^a UNIVERSITY OF GDA SK   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARAN SULFATE; OLIGOSACCHARIDE;

AGGRESSION; ARTICLE; CHEMICAL REACTION; CHEMICAL STRUCTURE; CHILD BEHAVIOR; DEGRADATION KINETICS; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; MUCOPOLYSACCHARIDOSIS; NEUROPATHY; SANFILIPPO SYNDROME; SLY DISEASE;

BEHAVIORAL SYMPTOMS; BRAIN; CHILD; GLYCOSAMINOGLYCANS; HUMANS; MUCOPOLYSACCHARIDOSES; NEURONS;

EID: 77958481823     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.07.044     Document Type: Article

References (33)

1. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. The metabolic and molecular bases of inherited disease 2001, 3421-3452. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Wegrzyn G., Wegrzyn A., Tylki-Szymanska A. A general model for genetic regulation of turnover of glycosaminoglycans suggests a possible procedure for prediction of severity and clinical progress of mucopolysaccharidoses. Med Hypotheses 2004, 62(6):986-992.
3. Piotrowska E., Jakobkiewicz-Banecka J., Tylki-Szymanska A., Czartoryska B., Wegrzyn A., Wegrzyn G. Correlation between severity of mucopolysaccharidoses and combination of the residual enzyme activity and efficiency of glycosaminoglycan synthesis. Acta Paediatr 2009, 98(4):743-749.
4. Al Sawaf S., Mayatepek E., Hoffmann B. Neurological findings in Hunter disease: Pathology and possible therapeutic effects reviewed. J Inherit Metab Dis 2008, 31(4):473-480.
5. Terlato N.J., Cox G.F. Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genet Med 2003, 5(4):286-294.
6. Valstar M.J., Ruijter G.J., van Diggelen O.P., Poorthuis B.J., Wijburg F.A. Sanfilippo syndrome: A mini-review. J Inherit Metab Dis 2008.
7. Bermudez A.J., Johnson G.C., Vanier M.T., Schroder M., Suzuki K., Stogsdill P.L., et al. Gangliosidosis in emus (Dromaius novaehollandiae). Avian Dis 1995, 39(2):292-303.
8. Constantopoulos G., Dekaban A.S. Neurochemistry of the mucopolysaccharidoses: brain lipids and lysosomal enzymes in patients with four types of mucopolysaccharidosis and in normal controls. J Neurochem 1978, 30(5):965-973.
9. Constantopoulos G., Iqbal K., Dekaban A.S. Mucopolysaccharidosis types IH, IS, II, and IIIA: glycosaminoglycans and lipids of isolated brain cells and other fractions from autopsied tissues. J Neurochem 1980, 34(6):1399-1411.
10. Constantopoulos G., Shull R.M., Hastings N., Neufeld E.F. Neurochemical characterization of canine alpha-l-iduronidase deficiency disease (model of human mucopolysaccharidosis I). J Neurochem 1985, 45(4):1213-1217.
11. Hara A., Kitazawa N., Taketomi T. Abnormalities of glycosphingolipids in mucopolysaccharidosis type III B. J Lipid Res 1984, 25(2):175-184.
12. Li H.H., Yu W.H., Rozengurt N., Zhao H.Z., Lyons K.M., Anagnostaras S., et al. Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase. Proc Natl Acad Sci U S A 1999, 96(25):14505-14510.
13. McGlynn R., Dobrenis K., Walkley S.U. Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J Comp Neurol 2004, 480(4):415-426.
14. Russell C., Hendson G., Jevon G., Matlock T., Yu J., Aklujkar M., et al. Murine MPS I: Insights into the pathogenesis of Hurler syndrome. Clin Genet 1998, 53(5):349-361.
15. Siegel D.A., Walkley S.U. Growth of ectopic dendrites on cortical pyramidal neurons in neuronal storage diseases correlates with abnormal accumulation of GM2 ganglioside. J Neurochem 1994, 62(5):1852-1862.
16. Van Dessel G., Lagrou A., Martin J.J., Ceuterick C., Dierick W. Two cases of mucopolysaccharidosis type III (Sanfilippo). A biochemical study. J Neurol Sci 1979, 40(2-3):77-86.
17. Avila J.L., Convit J. Inhibition of leucocytic lysosomal enzymes by glycosaminoglycans in vitro. Biochem J 1975, 152(1):57-64.
18. Baumkotter J., Cantz M. Decreased ganglioside neuraminidase activity in fibroblasts from mucopolysaccharidosis patients. Inhibition of the activity in vitro by sulfated glycosaminoglycans and other compounds. Biochim Biophys Acta 1983, 761(2):163-170.
19. Kint J.A., Dacremont G., Carton D., Orye E., Hooft C. Mucopolysaccharidosis: secondarily induced abnormal distribution of lysosomal isoenzymes. Science 1973, 181(97):352-354.
20. Walkley S.U., Vanier M.T. Secondary lipid accumulation in lysosomal disease. Biochim Biophys Acta 2009, 1793(4):726-736.
21. Walkley S.U. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin Cell Dev Biol 2004, 15(4):433-444.
22. Jakobkiewicz-Banecka J., Piotrowska E., Narajczyk M., Baranska S., Wegrzyn G. Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci 2009, 16:26.
23. Fuller M., Rozaklis T., Ramsay S.L., Hopwood J.J., Meikle P.J. Disease-specific markers for the mucopolysaccharidoses. Pediatr Res 2004, 56(5):733-738.
24. Fuller M., Brooks D.A., Evangelista M., Hein L.K., Hopwood J.J., Meikle P.J. Prediction of neuropathology in mucopolysaccharidosis I patients. Mol Genet Metab 2005, 84(1):18-24.
25. Bhattacharyya R., Gliddon B., Beccari T., Hopwood J.J., Stanley P. A novel missense mutation in lysosomal sulfamidase is the basis of MPS III A in a spontaneous mouse mutant. Glycobiology 2001, 11(1):99-103.
26. Bhaumik M., Muller V.J., Rozaklis T., Johnson L., Dobrenis K., Bhattacharyya R., et al. A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 1999, 9(12):1389-1396.
27. Birkenmeier E.H., Davisson M.T., Beamer W.G., Ganschow R.E., Vogler C.A., Gwynn B., et al. Characterization of a mouse with beta-glucuronidase deficiency. J Clin Invest 1989, 83(4):1258-1266.
28. Clarke L.A., Russell C.S., Pownall S., Warrington C.L., Borowski A., Dimmick J.E., et al. Murine mucopolysaccharidosis type I: Targeted disruption of the murine alpha-l-iduronidase gene. Hum Mol Genet 1997, 6(4):503-511.
29. Haskins M.E. Animal models for mucopolysaccharidosis disorders and their clinical relevance. Acta Paediatr Suppl 2007, 96(455):56-62.
30. Muenzer J., Lamsa J.C., Garcia A., Dacosta J., Garcia J., Treco D.A. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl 2002, 91(439):98-99.
31. Sands M.S., Birkenmeier E.H. A single-base-pair deletion in the beta-glucuronidase gene accounts for the phenotype of murine mucopolysaccharidosis type VII. Proc Natl Acad Sci U S A 1993, 90(14):6567-6571.
32. Wang D., Shukla C., Liu X., Schoeb T.R., Clarke L.A., Bedwell D.M., et al. Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation. Mol Genet Metab 2010, 99(1):62-71.
33. Bellettato CM, Scarpa M. Pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis 2010; (DOI: 10.1007/s10545-010-9075-9).